COMPANY PROFILE

Xenikos

Developing a novel therapy that aims to reset the immune system of patients suffering from serious immune diseases or rejection after transplantation

Nijmegen, NetherlandsFounded 2009Biotech & Life Sciences

Valuation $100–250M Last recorded · 2018

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Xenikos

Developer of anti-T-cell antibodies designed to provide immunotherapy medicines to help restore patients' health. The company uses a therapeutic tool for resetting the body's immune system which once injected into the body, specifically identifies and eliminates adult T cells, with a strong preference for the activated ones, enabling the medical community to optimize treatment outcomes associated with serious immune diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2009
Headquarters: Nijmegen, Netherlands
Employees: 1
Open positions: None listed
Dealroom signal: 59.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Antibodies, Immune System, Biotech and Pharma, EIC Fund, Hard Tech, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBT✓Debt	Sep 2021	$44M	—	RA Capital Management · Oost NL - Eastern Netherlands Regional Development Agency · Medicxi · Veloxis Pharmaceuticals	—
SERIES B✓Equity / VC	May 2018	$33M	$132M	Medicxi · RA Capital Management	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Xenikos website traffic

Latest recorded traffic for Xenikos is 280 monthly website visits, down 34.9% over the last three months. Xenikos's team grew 0% over the past year.

Latest monthly visits280 3-month web change-34.9% 1-year team growth0%

Monthly website visitsMay 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OSOsivaxA company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections	Lyon, France	Operational	60	$79M	$44M
XEXenotheraDeveloping improved immunological treatments using their glyco-humanized antibody platform	Nantes, France	Operational
ARArsanisAddressing critical infectious disease threats with targeted monoclonal antibody immunotherapies	Waltham, United States	Closed
AAAlginor ASAAlginor's green innovation, AORTA, increases the utilisation ratio of seaweeds from approximately 15 to 100% without using formaldehyde and other harmful chemicals	Haugesund, Norway	Operational
ITIGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors	London, United Kingdom	Operational
FAFabentechSpecializes in the development and production of emergency treatments to combat the risks of bioterrorism and emerging infectious diseases that are priorities for public health	Lyon, France	Operational
HPHerantis PharmaInnovative biotech company developing disease modifying therapies for Parkinson’s disease	Helsinki, Finland	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational